Signarama Canada first global franchise group to rollout solution
TORONTO, January 29, 2015 — CoursePeer Inc. and National Franchise Group have partnered to launch Franchise University, a service offering global franchise groups a powerful cloud-based training and collaboration solution for their franchisees. Signarma Canada, the global sign industry leader ranked 28th on Franchise Direct's Top 100 Global Franchises list, is among the first brands to join.
CoursePeer, a University of Toronto and MaRS Innovation company that provides learning and collaboration solutions for enterprise ...
Researchers working in orphan indications, immuno-oncology, respiratory diseases, diabetes, and other key areas invited to submit a brief Statement of Interest
The MaRS Innovation Industry Access Program (MI-IAP) is a simple, formalized process for marketing early-stage technologies to MI's industry partners: Baxter, LifeLabs (formerly CML Healthcare), GSK, Johnson & Johnson, Pfizer and IRICoR/Merck.
The program's goal is to secure funding for researchers within MI's membership through these collaborative, strategic R&D partnership programs.
The program is open to any researcher affiliated with MI's 16 member ...
UTEST company Onyx Motion, makers of an Android wear app called Swish that provides digital coaching for sports like basketball, will appear on CBC's NextGenDen.
UPDATED! You can watch the Onyx Motion/Swish episode here (jump to the 6:15 mark).
The online web series seeks to take the popular Dragon's Den model to Internet- and mobile-focused companies and features a new panel of dragons: Michael Hyatt, Michelle Romanow, Paul Miklas and Matthew Corrin.
Onyx Motion, led by CEO Marissa Wu and CTO Vivek Kesarwani, will ...
TORONTO (January 21, 2015) — MaRS Innovation and the University of Toronto (U of T) are pleased to announce that the founders of Granata Decision Systems Inc., a graduate of the University of Toronto Early-Stage Technology (UTEST) start-up incubator program, have joined Google Inc.
This story was covered in TechVibes.
Dr. Craig Boutilier is a professor in U of T’s Department of Computer Science. He and Tyler Lu, a graduating PhD student in the same department, co-founded Granata Decision Systems in 2012 to ...
MaRS Innovation is a My Virtual Dream event sponsor and commercialization partner
Toronto, ON (January 12, 2015) – Baycrest Health Sciences’ dazzling brain science exhibit from 2013 Scotiabank Nuit Blanche will be on show at the Ontario Science Centre’s BRAINFest, Jan. 17-18.
My Virtual Dream is an innovative and interactive live performance experience at the intersection of science, art and music. The installation will enable participants to use their brain waves to communicate with each other through an immersive audio and visual expression that ...
MaRS Innovation enjoyed an exceptional year in 2014. Our team continues to collaborate with researchers within our membership to help bridge the commercialization gap between their world-leading research and creating successful start-up companies or licenses.
Here are our picks for the top 10 news stories from MaRS Innovation's portfolio.
1. Triphase Accelerator Corporation, in which MaRS Innovation is an investor, started the year with a bang by signing a collaboration and option agreement with Celgene Corporation. In October, Triphase initiated a Phase I clinical study ...
"The first disclosed grant under Merck & Co. Inc.'s Canadian translational initiative will bolster the ability of macrocycle-based Encycle Therapeutics Inc. to conduct lead optimization of its integrin [a4b7,] inhibitors for inflammatory bowel disease," writes Michael J. Haas in SciBX's feature on the partnership, "Merck Encycles through Canada." The article appears in the publication's December 4, 2014 issue.
Read the Encycle press release that prompted this article.
The article explores the current grant partnership between Merck, Encycle Therapeutics, MaRS Innovation, the Institute for ...
Findings from Preclinical Study Presented at American Society of Hematology 2014 Annual Meeting
TORONTO AND SAN DIEGO (Dec. 6, 2014) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase II proof-of-concept clinical studies, today announced preclinical study results demonstrating that the combination of its highly differentiated proteasome inhibitor, marizomib, and pomalidomide (Pomalyst®) was synergistic in killing multiple myeloma cells.
MaRS Innovation is an early-stage investor in Triphase. See our web archive for more details.
Combined doses of ...